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Antibiotic resistance has become an important health threat across the world dur-
ing recent years. One of the solutions to reduce antibiotic resistance is to find ways
in order to use efficient amounts of antibiotics in treatments. It has been seen that
some antibiotics are synergistic, i.e, if they are administered together, they will
boost the individual antibacterial and antifungal effects. Identification of syner-
gistic antibiotics can be of significant assistance to medical practitioners in order
to optimize the amount of antibiotics to be used. In this thesis we have conducted
a set of analyses using data mining based approaches. Chemogenomic profiles
and chemical properties of drugs have been utilized to predict synergy between
them. Two datasets, E. Coli and yeast were used in order to perform the analysis.
GRASP meta-heuristic algorithm was implemented on chemogenomic features in
order to predict synregies which yielded in 0.94 accuracy and 0.82 Area Under
ROC curve for E. Coli dataset. In order to further explore the chemogenomic
features, we suggest a novel algorithm to predict synergy. This algorithm resulted
in Area Under ROC curve and accuracy of 0.71 and 0.91, respectively for E. Coli
dataset. Next, two chemical features, XLogP3 and Q PC- were used to perform
the analysis by employing decision trees and random forest classifiers. Our analysis
indicate that Q PC- chemical feature can be as discriminative as XLogP3 which
has been used in literature previously. Employing chemical features resulted in
most accurate prediction among the implemented methods. In this thesis, details
of the above-stated methods and algorithms will be presented.
O¨ZET
MILAD HASSANI
Endu¨stri mu¨hendislig˘i, Master Tezi, Ag˘ostos, 2016
Tez Danıs¸manı: Doc¸. Dr. Kemal Kılıc¸
Son yıllarda antibiyotik direnci du¨nya c¸apında o¨nemli bir sag˘lık tehdidi sırasında
haline gelmis¸tir. Antibiyotik direncini azaltmak ic¸in c¸o¨zu¨mlerden biri tedavi sırası-
nda antibiyotiklerin uygun miktarda kullanılmasının sag˘lanmasıdır. Bazı antibiy-
otiklerin sinerji oldukları, yani birlikte uygulandıg˘ı takdirde, tek bas¸larına sahip
oldukları antibakteriyel ve antifungal etkilerin arttıg˘ı bilinmektedir. Antibiyotikler
arasındaki sinerjinin belirlenmesi, c¸es¸itli durumlarda kullanılacak olan antibiyotik
miktarlarının optimizasyonuna katkı sag˘layabileceg˘inden, tıbbi uygulamacılar ic¸in
o¨nemli bir fayda sag˘layacaktır. Bu tezde veri madencilig˘i tabanlı yaklas¸ımlar kul-
lanılarak antibiyotikler arası sinerjinin belirlenmesi problemine yo¨nelik bir takım
analizler yapılmıs¸tır. Bu kapsamda ilac¸ların chemogenomic profilleri ve kimyasal
o¨zellikleri kullanılarak birbirleri arasındaki sinerjinin tahmin etmeye yardımcı ola-
cak yeni yo¨ntem ve yaklas¸ımlar gelis¸tirilmis¸tir. Gelis¸tirilen yo¨ntem ve yaklas¸ımlar
E. Coli ve maya verileri kullanılarak performansları kars¸ılas¸tırılmıs¸tır. Chemoge-
nomic profillerin kullanılmasına dayanan yaklas¸ımlar arasında yer alan GRASP
meta-sezgisel algoritması 0.94 dog˘ruluk ve 0.82 AUC sonucuyla E.Coli veri ku¨mesi-
nde en iyi sonucu vermis¸tir. O¨te yandan topoloji verilerinin de o¨g˘renme su¨recinde
kullanılması amacıyla gelis¸tirilen orijinal bir yaklas¸ımla gene E. Coli veri ku¨mesinde
sırasıyla 0.91 ve 0.71, dog˘ruluk ve AUC sonucuna ulas¸ılmıs¸tır. O¨te yandan tez kap-
samında ayrıca ilac¸ların kimyasal o¨zellikleri verisinin kullanılması durumunda ne
yapılabileceg˘i u¨zerinde durulmus¸tur. Bu kapsamda, karar ag˘ac¸ları ve karar or-
manları gibi yo¨ntemlerin de kullanılmasıyla yapılan c¸es¸itli c¸alıs¸malar sonucunda
iki o¨zellig˘in (XLogP3 ve Q PC) sinerji ilis¸kisinin belirlenmesi kapsamında dig˘er 300
civarındaki kimyasal o¨zellig˘e go¨re daha c¸ok yardımcı olabileceg˘i belirlenmis¸tir. Her
ne kadar XLogP3 bilimsel yazında zaten bu kapsamda etkili bir o¨zellik olarak daha
o¨nceden belirlenmis¸ ise de, yapılmıs¸ olan analizler Q PC’nin de XLogP3 kadar is¸e
yarar olabileceg˘ini go¨stermektedir. Bu tez de bu kapsamda gelis¸tirilen yaklas¸ımlar,
yo¨ntemler ve bunların performanslarının belirlenmesine yo¨nelik yapılan c¸es¸itli anal-
izlerin sonuc¸ları sunulmaktadır.
Anahtar Kelimeler: Veri Madencilig˘i, Algoritmalar, I˙lac¸ Etkiles¸imi, Sinerjik I˙lis¸kiler,
Antibiyotikler, Antibiyotik Direnci
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Chapter 1
INTRODUCTION
1.1 Motivation
Humankind has always searched for solutions to the problems that takes place
in his/her body. Early written evidence of such endeavors date 2500 BC where
certain types of plants have been used to cure diseases in Egyptian civilization [1].
Each medical plant’s usefulness to treat a category of illnesses had been identified
by medical practitioners of this ancient civilization. Researchers in [1] suggest
that these discoveries had been based on the physical properties of the plants. For
example, Figure 1.1 depicts perforated leaves of St John’s wort which suggests a
benefit in healing perforated wounds. Similarly, in Ayruvedic medical tradition
in India, Azadirachta Indica or neem leaves were used as a natural remedy for
bacterial infections, antiseptic treatment, oral hygiene, parasite infection, fevers,
and general infections [4]. Although traditional medical systems were effective
in treating certaint types of infections and boosting general immune system, they
were not able to provide solutions for all infections especially with global prevalence
of infectious diseases in 18th and 19th century.
1
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Figure 1.1: Ancient societies used St. John’s wort to heal perforated wounds
based on the shape of its leaves [1].
In 1928, Alexander Flemming, introduced the first chemical compound, Penicillin,
which fights the bacteria and/or inhibits its growth. This discovery was effective
in controlling infectious diseases which in turn led to a revolution in the medical
sciences in 20th century. The term antibioisis means against life and was first
introduced in a research paper published by William Roberts in 1874. Roberts
observed and reported that the liquid in which the Penicillium glaucum existed
could not be infected with bacteria [5].
Although antibiotics are not proven to be effective in battling diseases which are
caused by viruses, bacteria based disorders can be effectively cured using this type
of drugs. Infectious diseases such as tuberculosis, which was the cause for 25% of
deaths during 19th century, have been prevented in developed countries [6].
Since the first introduction of antibiotics in medicine many new infections have
been discovered and accordingly scientists have been constantly trying to find new
antibiotics to defeat them. At the same time many lives have been saved and the
use of antibiotics has significantly improved public health globally.
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Antibiotic drug consumption has increased by 36% during 2000-2010 period. This
increase has happened mainly in developing countries [7]. Although drug accessi-
bility is a life saving opportunity for the individuals who were previously unable
to provide these drugs for themselves, over-consumption of antibiotics results in
antibiotic resistance which is currently considered as a major public health threat
[7]. That is to say, antibiotic resistance is a serious problem facing global health
that is caused by misuse and overuse of antibiotics.
When antibiotic resistance occurs, a microbe evolves such that it resists the chem-
ical compounds which aimed to kill it. This resistance can be partial or total.
In total resistance, presence of the drug makes no difference in the growth of the
bacteria and in partial resistance, the drug kills only a percentage of the bacteria.
In order to prevent resistance issue, promoting rational use of antibiotics and
educating communities about the effects and dangers of antibiotic resistance seems
to be essential. Studying efficacy of drugs in cases where multiple number of
antibiotics are required is one of the ways to help physicians optimize the amount
and type of the antibiotic administered.
Researchers have previously studied the effects of using two drugs at the same time
and the process is referred to as drug-drug interaction. Many of such research is
based on purely experimental procedures, in which bacteria is grown in laboratory
and a combination of drugs are introduced to it in order to observe the combined
effects of drugs on bacteria’s growth. However, these methods are expensive and
time consuming, which limits the number of interactions that can be examined.
Employing data-mining (DM) can significantly assist in exploring drug-drug in-
teractions. By applying these techniques it is possible to discover and study a
greater number of drug-drug interactions. Although experimental data is needed
in training phase of the DM procedures, implementing these methods brings the
possibility of predicting drug interactions for which experimental data does not
exist. That is to say, researchers can learn from existing data and predict those
that are not available by using tools provided in DM. Despite the fact that there
are several articles in literature that incorporate Machine Learning (ML) in this
problem, there is still open research questions both in terms of the methodologies
and their applications.
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In this thesis, we have examined various approaches that employs DM techniques
in order to predict the synergistic drug-drug interactions. Performance of the
developed nethodologies are assessed in two datasets, namely, E. Coli and yeast.
The rest of the thesis is organized as follows. In Chapter 2 we will introduce
terminology and define the problem. Relevant literature will also be provided in
that chapter. Next, one of the approaches that utilize topological information will
be presented in Chapter 3 and the performance of the proposed approach will be
evaluated in E. Coli and yeast datasets. Chapter 4 will follow the same structural
flow in which non-topological approaches will be introduced and evaluated with the
same datasets. In Chapter 5, we will introduce chemical features to the problem
and present our proposed approaches. We will conclude the thesis in Chapter 6
with some insights we gained from the experimental analysis and further research
topics that are worth to be examined.
Chapter 2
Problem Statement and Relevant
Literature
In this chapter we will first introduce the basic terminology and the relevant lit-
erature of the synergistic drug-drug interaction prediction problem that we will
focus in the thesis. Next, we will provide the details of the datasets that will be
used in the analysis.
2.1 Drug-drug Interaction
The history of studying interactions among drugs can be traced back to tradi-
tional Chinese medicine and Indian medicine, Ayurveda. In traditional systems of
medicine, practitioners combined herbal extracts and plants in order to increase
the effects on a particular disease. These methods were developed by observing
each individual empirically and proposing a solution based on the patient’s par-
ticular characteristics [8]. One of the most popular fixed formulas in Ayurveda
is “Trikatu.” This mixture combines black pepper (Piper Nigrum), long pepper
(Piper Longum), and ginger (Zingiber Officinalis) [9][10]. It has attracted the at-
tention of phyto-medicine practitioners recently in an experiment and it is discov-
ered that “Trikatu” increases the blood level of vasicine significantly, which is an
antiasthmatic drug [10]. It appears that Trikatu mixture increases bio-availability
of drugs by providing rapid absorption in garstointestinal tract or prevention of
drug oxidization in its first passage through liver [10].
5
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One of the disadvantages of using traditional systems of medicine is that geo-
graphical location and seasonality of the place of production for the medical plant
is significantly influenced in their efficacy [8]. For example, researchers compared
chemical compunds in two extracts of Brazilian Orchid Tree (Bauhinia forficata)
from two different geographical areas and harvested in the same period of the year,
and the results suggest that the extracts present different concentration of their
main marker [8]. Despite their efficacy in dealing with chronic ailments, tradi-
tional medicine has not been proven to be successful in combating new infectious
diseases and as a consequence, they are rarely practiced.
Drug interaction is investigated from two major points of view. Some try to
investigate drug interaction type using pure biological experiments while some use
computational methods and bioinformatics for prediction.
In pure biological studies each drug combination is applied to cultures of the
biological entity and growth curves over a time period are reported. Growth
conditions consist of multiple dosages for each one of the drugs. Growth curves
indicate the number of grown cells at any specific time. Drug interaction type
is then determined based on these growth graphs. E. Coli is one of the most
researched bacterium in the literature. Some groups have also done experiments
on yeast cultures [2].
As possible combination of drugs is extremely large, determining interaction types
using pure biological methods for every combination is not possible in reality. In
addition, sometimes experiments are repeated several times to prove their repro-
ducibility, which is both expensive and time consuming. Computational methods
bring the possibility of predicting drug interaction type using a reduced number
of experiments. Using computational methods, the type of new drug interactions
is predicted based on features extracted from the biological experiments.
Each of the above-stated ways to approach drug synergy prediction can be used
for finding synergy in different types of cells.
Here we will introduce the basic terminology and review previous studies done in
the field of drug synergy prediction in literature.
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2.1.1 Measuring synergy
When two drugs are administered together they may interact in three different
ways [11]:
• They might have expected efficacy of each drug as in the case that they are
administered individually, which are called as additive drugs.
• They may have an efficacy higher than what it is expected from each one of
the drugs; in this case these two drugs are said to be synergistic.
• One may inhibit the other one to function, thus, using two drugs together
have less efficiency as using each one of them separately, which are called
antagonistic drugs.
These three possible ways of interaction are depicted in Figure 2.1. X axis repre-
sents ratio between the dose of agent 1 when used in combination with agent 2,
D1, to the dose of agent 1 in isolation, DIx,1, for the same biological effect. Axis Y
represents the same ratio for agent 2 [8]. Concave line, i.e. when the curve moves
towards the origin, indicates that the agents in the mixture are synergic, and when
the opposite occurs (convex line) they present antagonism. In other words, the
same biological effects of the agents in isolation are obtained at lower (or higher)
doses of the mixture.
Figure 2.1: Drug interaction types of combined agents.
Synergistic interaction is of more interest as it allows treatment of the disease with
less dosage of drugs. Administration of synergistic drugs results in reduction in
Problem Statement and Relevant Literature 8
toxicity and side effects while the efficacy is increased or remains the same [11].
Combinatorial therapies that impact multiple targets inside the cell simultaneously
are less prone to development of drug resistance, and thus they increase therapeutic
efficacy [12]. Although in this thesis we study using a combinatorial therapeutic
approach in treating infectious diseases, they are now standard in tackling other
diseases as well, such as cancer, diabetes [12], AIDS, malaria and hypertension [8].
There are four main mechanisms that drug synergy might occur [2].
• Drugs impact separate targets to create a combination effect.
• One drug alters the ability of another to reach its target.
• The components bind separate sites on the same target to create a combi-
nation effect.
• Two drugs physically interact to make a new chemical entity.
In order to discover how two drugs interact, a target cell is cultured in a matrix
which is called dose matrix, i.e., growth matrix [3]. Each plate has a different
concentration of drug 1 and 2. For example, in Figure 2.2 concentrations of drug
A and B are increased in eight steps and combination of both has been applied
to the culture of cells. Each subplot in Figure 2.2 represents number of cells
present in culture over a period. X axis in the subplots represent time and Y axis
represents number of cells in culture. The type of interaction between the drugs
are determined by the shape of Minimum Inhibitory Concentration (MIC ) curve
obtained from the experiments.
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Figure 2.2: Drug interaction diagram when drug A and drug B have synergy[2]
MIC, is the lowest drug concentration that prevents visible growth of the target
microorganism. In synergistic interaction connecting MIC concentrations in the
dose matrix, results in a concave line.
When drug A and B have synergy, they kill the bacteria faster, in other words, in
the first column of graphs in Figure 2.2, when there is no drug A in the solution,
it takes seven units of drug B to kill the bacteria completely, but by introducing
just one unit of drug B to the solution, it takes just 2 units of drug A to kill the
bacteria completely. This method of representing drug interaction is called Loewe
additivity model [13].
Figure 2.3 represents an example of real dose-matrix responses obtained in an
experiment. Tunicamycin and Ciclosporine A are suggested to be synergistic in
attacking Saccharomyces cerevisiae [3]. Each circle in Figure 2.3 depicts a colony of
grown cells. Brighter spots implies more cells have survived to grow in comparison
to darker spots. Since the MIC curve is concave, Tunicamycin and Cyclosporin A
are synergistic.
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Figure 2.3: Dose matrix response of two antibiotic drugs which show synergy
[3]
On the other hand when drugs are additive, they neither boost nor prohibit their
effects, i.e., adding one more units of drug A to the growth environment kills the
same number of bacteria cells as adding one unit of drug B. Loewe additivity
model for additive drugs is represented in Figure 2.4.
By means of such experimental analysis, it is possible to identify the type of
interaction of drugs in different target bacteria. However, it is costly due to the
time required and money spent. Data-mining methods, on the other hand, use
known interactions to predict unknowns which saves both in terms of money and
time. In the literature, some research is available that uses chemogenomic profiles
while some use chemical features as an alternative. Now we will introduce the
literature that utilizes these two approaches.
Problem Statement and Relevant Literature 11
Figure 2.4: Loewe additivity model when drug A and drug B are additive [2]
2.1.2 Chemogenomic profiling
Researchers have developed different methods to predict whether two drugs are
synergistic or not. One of these methods is to employ chemogenomic profiles
of the drugs that interact. Chemogenomic profiles are an output of a research
discipline known as chemogenomics. In this field, researchers find genomic response
of a biological entity to chemical compounds [14]. When a chemical compound is
introduced to a cell or a biological entity, it will target products of one, or more
gene(s) which in turn inhibits that gene from expression. In other words, with
chemogenomic profiling it is possible to find which gene is affected by a specific
drug [14].
In order to access the chemogenomic profile of a drug, a gene is removed from
bacterium’s genome and a stress is introduced to that phenotype, then that phe-
notype is arrayed on agar plates1. Number of bacteria cells which are present on
the agar plate after applying the stress over a period of time is estimated. Based
on this estimation, which is done by multiplying size of the colony by approximate
number of cells per unit of area for E. Coli, a score is calculated. This score is
proportional to expression level of the cells which lack the related gene. This score
1An agar plate is a dish which contains a growth medium and is used to culture microorgan-
isms. Other compounds such as antibiotics might also be added to the plate [15].
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is calculated for all gene deletions. The combined vector is the chemogenomic
profile of that particular type of cells.
Chemogenomic profiles have been used in drug synergy prediction in [3]. Authors
use hyperergeometric probability distribution and calculated a similarity measure
between chemogenomic profiles of two drugs involved in the interaction. If there
are x genes that are common in both profiles, similarity measure is the probability
of obtaining x or more genes that overlap between the two by chance. Similarity
measure can be considered as a p-value derived from hyper-geometric distribution
[3].
Note that, the approaches used in [3] does not utilize the topological features of
the drug-drug interaction network. In this thesis we will also develop an algo-
rithm which utilizes the topology information. Furthermore, we will introduce
alternative approaches that use genetic algorithms (GA) and Greedy Randomized
Adaptive Search Procedure (GRASP) which will not use topology information.
The algorithms that are based on the former approach will be presented in Chap-
ter 3 and the algorithms that are based on the other approach will be introduced
in Chapter 4.
2.1.3 Utilizing Chemical Features
Another approach in predicting drug synergy by data-mining methods is utilizing
the chemical features of the drugs. In [2] authors have found that synergy of drugs
based on their lipophilicity (LogP) values. LogP of a drug is by means of the oc-
tanolwater partition coefficient which is the relative solubility of a compound in
octanol over the solubility in water.
logP = log(
solute in octanol
solute in water
) (2.1)
A major advantage of this method is that logP of all compounds are known with
high precision and at no cost.
In [2] authors have defined synergicity of a drug as the ratio of number of synergies
of that drug with other drugs to number of experiments done on that drug. For
example, out of 24 drugs that Pantamidine was tested against, 12 of them were
synergistic and 12 non-synergistic which sets synergicity score of Pentamidine as
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0.5. Synergicity of a drug can be considered as a measure of willingness of a drug
to have synergy with others in a particular drug set.
Figure 2.5 (left) indicates that lipophilicity (XLogP3) is significantly correlated
with synergicity (Spearman correlation = 0.51, p-value = 0.0036). Diameter of
each circle corresponds with number of experiments done on that drug. Figure 2.5
(right) is histograms of XLogP3 distribution for non-synergistic (black) and syn-
ergistic (red) pairs. Two drugs with highest number of experiments (Pentamidine
and Terbinafine) are more likely to have synergy with lipophilic drugs [2].
Figure 2.5: (Left) Drug synergicity scores vs. drug lipophilicity for 31 drugs.
(right) is histograms of XLogP3 distribution for non-synergistic and synergistic
pairs
Since correlation between XLogP and synergicity is positive, it can be inferred
that if a drug has a higher lipophilicity it is more probable to have synergy with
other drugs, therefore, XlogP can be a good measure that cn be used in predicting
synergy among drugs. We can also observe in Figure 2.5 (right) that the drugs
with highest number of synergy experiments tend to show synergy with drugs that
have higher XLogP values which repeats the previous assumption.
Using chemogenomic dataset two approaches are developed; methods based on
topological data and non-topological methods. In experimental analysis that are
conducted both E. Coli and yeast are used. Next, we will summarize the datasets
that are used in the analysis.
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2.2 Datasets
When two drugs are used together three different possibilities arise. They might
be antagonistic, additive or synergistic. In this thesis we aim to predict synergy
of the drugs and we do not consider predicting neither additive nor antagonistic
interactions. We approach the problem using two different different approaches
and propose various algorithms for both. One of the approaches utilizes chemoge-
nomic profiles of the drugs involved in an interaction and the other uses chemical
properties of the drugs for the same purpose. We have used chemogenomic profiles
that have been discovered for E. Coli [17] and yeast [18] respectively.
In each of these researches, a series of experiments have been conducted on E. Coli
and yeast using different drugs in order to determine their chemogenomic profiles.
For each drug, different dosages have been applied and drug-gene scores have been
recorded in the relative chemogenomic profiles.
In order to select one of available profiles for a drug, the profile which has the
highest number of expressed genes was selected. An expressed gene is the one
which its drug-gene score is higher than a threshold in the profile, i.e. number
of grown cells which lack the gene passes a threshold when that drug has been
present in the cell culture. That is to say, by means of a threshold, the levels
(scores) are binarized. The threshold that is used to binarize profiles is set by the
domain experts.
Bacteria’s growth is prohibited not only by introducing drugs to it but also by
putting it under various physiologically relevant stresses. As we are going to
analyze the effects of drugs on E. Coli bacteria, we only consider chemogenomic
profiles when only a drug used as a stress factor.
Recall that MIC contour was used in order to determine the interaction type
between the drugs. The MIC curve is summarized by a metric refered to as alpha
score [20]. That is to say, alpha scores are extracted from dose matrices, explained
in Section 2.1, to indicate number of grown cells of the target cells (E. Coli or
yeast) when two drugs have been present in the culture. A low alpha score in
an interaction implies low number of grown cells, thus, we conclude that involved
drugs have effectively prohibited the growth of target cells, similarly, if the alpha
score is more than a threshold, which is again provided by experts, we can label
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the interaction as antagonistic. If the alpha score of an interaction is lower than
the threshold we consider the interaction as synergistic.
2.2.1 E. Coli Dataset
In [17] authors have compiled chemogenomic profiles of E. Coli in 324 conditions
for 3979 gene deletions extracted from Keio single-gene deletion library [19]. Out
of 324 conditions, 209 belongs to drugs including antibiotic, antimicrobial and
antifungal drugs [17].
Conditions to which gene deletions were introduced consists of 114 unique condi-
tions in different varietes, e.g. a drug is used as an stress in different dosages or
other physiological stresses have been applied.
The dataset of E. Coli contains
(
25
2
)
= 300 alpha scores of interactions between
25 drugs. In order to be able to validate interaction types which are predicted, a
subset of drugs are selected which we both have validation data and chemogenomic
profiles. After removing drugs that were not common between train and validation
sets, 19 drugs and
(
19
2
)
= 171 interactions among them were remained. Validation
dataset was extracted from [20].
2.2.2 Yeast Dataset
Chemogenomic profiles of yeast [18] were used in the analysis. In this dataset 726
conditions were applied on yeast’s 5985 gene deletions to find its chemogenomic
profiles. Interaction data available in supplementary materials of [2] were used to
compile required dataset for yeast. As the interaction data was in binary numbers,
i.e, synergy is represented by true and false otherwise, we used the same data and
did not apply a threshold on alpha scores. This dataset contains 175 interactions
among 33 drugs. Two different subsets were extracted to be used in validation
phase of the proposed algorithms. The first contains 165 pairs of 31 drugs and the
second includes 67 pairs of 21 drugs. Validation sets were selected according to
the type of features used for training. First set was used to validate the methods
based on chemical features, that will be discussed in Section 2.2.3, and the second
is used for the chemogenomic profile based prediction approaches.
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As chemical property that we use in proposed methods for yeast does not exist
for two drugs, i.e. Lithium and Cisplatin, we removed these two drugs and their
relevant interactions leaving the validation set with 31 drugs and 165 interactions
among them. Chemogenomic profiles of 22 drugs, with 68 interactions, exist in
yeast’s validation set. One drug in the dataset, Clozapine, has only one interac-
tion. We removed that interaction and drug in order to increase reliability of the
methods.
2.2.3 Chemical features
In the second method of drug interaction type prediction, chemical properties of
drugs are used in order to predict their interaction type. Our dataset consists of 328
chemical features for 31 drugs and 165 drug interactions. In this dataset interaction
data is not complete and instead of
(
31
2
)
= 465 interactions, we have a subset of
165. Our aim in this part is to investigate the possibility of predicting synergy
type using just one of the chemical features of the drugs in that interaction. The
advantage of using this method instead of using experimentally obtained features
is that chemical features are calculated mathematically with a predefined formula
which makes them significantly more reliable in comparison to the features based
on experiments. This fact helps us remove uncertainty caused by the experimental
procedure and improve the accuracy of predictions.
A set of analysis that had been done using XLogP3 has been published in [2]. Here
we first aim at reproducing the results found in [2] and secondly finding features
which did not have correlation with XLogP3 and result in reasonable Area Under
ROC and Area Under Precision Recall curve.
Chapter 3
Topology-Based Algorithm
3.1 Introduction
In this chapter a novel algorithm is proposed in order to predict drug synergy
based on synergy networks. A synergy network is a graph that depicts synergy
relationships among a set of drugs, i.e., nodes of the graph represent drugs, and
existence of an edge indicates that connected nodes are synergistic. Similarly,
antagonistic network can also be developed by considering edges when connected
drugs are antagonistic.
Synergistic and antagonistic pairs are determined by setting a threshold, extracted
from expert knowledge, on the alpha scores. If the score is less than synergistic
threshold we consider that interaction to be synergistic knowing the fact that
when alpha score is low, two drugs have effectively kill target cells (E. Coli or
yeast). If alpha score is higher than antagonistic threshold the pair is assumed
to be antagonistic. Synergy and antagony networks contain valuable information
that can be used to predict synergy. If a subset of drugs, i.e. a sub-graph, in the
network are fully connected and a common property can be found among them,
employing these properties may help us predicting synergistic pairs.
In this chapter we have utilized an algorithm to predict synergy using these com-
mon features. The following sections will provide details of this algorithm.
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Table 3.1: Binarization thresholds used in validation sets.
Antagony network Synergy network # of synergies
E. Coli 3 -0.5 20
Yeast 1 -0.5 17
Table 3.2: Maximal cliques in E. Coli synergy network and their nodes
Clique # 1 2 3 4 5 6 7 8 9 10 11
Nodes 1,7 2,7 7,14 3,5,7,16 3,6,7,16 7,13,16 7,16,19 8,16 10,11 13,18 18,19
3.2 Synergy and Antagony Networks
Synergy and antagony networks, as described in introduction section, depicts the
topology in which drugs interact. Thresholds used for binarizing alpha scores are
presented in Table 3.1 for the two datasets used in in the analysis.
Synergy and antagony networks of E. Coli dataset are represented in Figures 3.1
and 3.2 respectively. Recall that the existing dataset had 19 drugs for E. Coli,
on the other hand, chemogenomic profiles of 21 drugs are available for the second
yeast dataset. The synergistic and antagonistic networks of yeast are depicted in
Figures 3.3 and 3.4 respectively.
The proposed topology based algorithm utilizes maximal cliques that are available
in the networks. Maximal cliques are complete sub-graphs which form a complete
connectivity inside the subset. In other words, cliques are complete sub-graphs of
a network.
Bron-Kerbosch algorithm [21] is used to determine all maximal cliques in both
synergy and antagony graphs of E. Coli and yeast.
E. Coli and yeast synergy networks consist of 11 maximal cliques listed in Tables
3.2 and 3.4 respectively. Note that we used Leave One Out strategy in the analysis.
According to this strategy every time a drug is removed from the dataset and used
as the test drug in order to evaluate the performance of the algorithm, the structure
of the graph will change, which consequently modifies number of maximal cliques.
For example if drug #7 is used as test drug in E. Coli dataset, there will be eight
cliques which are represented in Table 3.3.
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Table 3.3: Maximal cliques in E. Coli dataset when drug 7 is left out as test
drug.
Clique # 1 2 3 4 5 6 7 8
Nodes 10,11 3,5,16 3,6,16 8,16 13,16 16,19 13,18 18,19
Figure 3.1: Synergy network for E. Coli dataset. Connected nodes represent
synergistic pairs.
Figure 3.2: Antagony network for E. Coli dataset. Connected nodes represent
antagonistic pairs.
Yeast’s synergy and antagony network is provided in 3.3 and 3.4
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Figure 3.3: Synergy network for yeast dataset. Connected nodes represent
synergistic pairs.
Table 3.4: Maximal cliques in yeast synergy network and corresponding nodes
Clique # 1 2 3 4 5 6 7 8 9 10 11
Nodes 1,2,6 1,2,7 1,2,8 2,4,7 2,5,6 2,5,7 2,5,8 2,12 2,13 2,17 20,21
Figure 3.4: Antagony network for yeast dataset. Connected nodes represent
antagonistic pairs.
3.3 Topological Algorithm
Our proposed method is structured in two phases. In the first phase we make a set
of possible synergistic pairs which we call “suggested synergies” and in the second
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phase, suggested synergies are filtered to remove less probable predictions. The
following sections present the steps of each phase in the algorithm.
3.3.1 Finding Possible Synergies
A threshold, extracted from expert knowledge, was used to convert drug chemoge-
nomic profiles into binary vectors. In the converting process, if a drug-gene score is
over this defined threshold, binary value will be true and false otherwise. Thresh-
old of -0.5 was used for E. Coli and -1 for yeast. Leave-One-Out cross validation
concept was performed by leaving one drug and its relevant data as test data and
using other drugs as training set.
Binary chemogenomic profiles were used as an input for Algorithm 1. Dti and DC
parameters used in Algorithm 1 are explained in Section 3.3.1.3.
Data: binarized chemogenomic profiles
Result: “suggested synergies” set
for all drugs in dataset do
select drug as “test drug”;
remove test drug from the network;
find maximal cliques;
for each maximal clique do
extract discriminative features set;
calculate distance matrix;
end
if Dti < DC then
add ith drug in clique and test drug to “suggested synergies”;
end
end
Algorithm 1: Topological based synergy prediction - creating suggested synergies
set
3.3.1.1 Discriminative Features
A subset of features(gene deletions) were selected for each clique which we refer
to as “discriminative features”. This subset is used in order to calculate distance
matrices. Recall that features have binary values after the binarization process.
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Three possible cases exist for a feature value inside and outside of a clique,
• A feature value can be true in clique drugs’ profiles and false for others.
• It can be false for clique drugs and true for others.
• Feature’s value can be the same in clique and non-clique drugs, i.e. both
true or both false.
Features which fit in first and second cases are possibly discriminative in finding
synergies. Based on this observation we suggest the following: If a feature has the
same value, e.g. true, among all clique drugs and is in lower s percentile of the
other binary value, i.e. false we include them in “discriminative features”. For
example, value of feature f is true for both drug d1 and d2 which are members of
clique c in E. Coli dataset and in only one of the remaining 17 drugs f value is
true, therefore, we include this feature to discriminate features related to clique c.
This process is repeated for each maximal clique as indicated in Algorithm 1.
As structure of network changes for each test drug, feature selection was done
for each test drug network separately. We performed the same procedure for
synergy and antagony networks of each dataset. Two cases were considered for
both antagony and synergy network, therefore, total number of extracted feature
subsets equals to
∑
DNCD ∗ 4. Where NCD is number of cliques for corresponding
drug D.
3.3.1.2 Distance Matrices
Distance matrices were calculated as a means to form classification. A distance
matrix contains pairwise euclidean distances of drug chemogenomic profiles based
on the subset of features determined. That is to say, only discriminative features
are used to generate the distance matrices. For example when dt is selected as test
drug in E. Coli dataset, features selected for clique c earlier in the algorithm is
represented as a vector which is a subset of drugs’ chemogenomic profiles. This sub-
profile is extracted for all 19 drugs and euclidean distance between each possible
pair of these sub-profiles is calculated to form distance matrix of clique c. Distance
matrices of all cliques are formed and stored as distance matrices for each test drug
dt.
Topology Based Algorithm 23
Distance matrices are square with ND rows and columns, where ND indicates
number of drugs in the dataset. Test drug is included in the process of calculating
distances as there is a need to find distance between test drug and the drugs in
the clique drugs. Inclusion of test drug in matrices does not bring circularity as
distance values are not used in training part of the algorithm and is only used
later in order to find synergies of the test drug.
We calculate a matrix for each member of discriminative features set, therefore,
again a total of
∑
DNCD ∗ 4 distance matrices exist.
3.3.1.3 Suggested Synergies
We first calculate average distance, DC , between each clique drug and other non-
clique drugs using the distance matrices of all cliques. Non-clique drugs set in-
cludes all drugs except the ones in the corresponding clique and the test drug.
If test drug’s distance with any of clique drugs is less than DC , we consider test
drug and that specific clique drug as a possible synergistic pair. M will be an
average of ND −NDC − 1 numbers where NDC is number of drugs in clique.
Distance matrices of both cases discussed in section 3.3.1.2 were used to obtain a
set of synergy suggestions. Using selected features, clique drugs have an average
profile distance, DC , among themselves and test drug has a distance, Dti , with
ith member of drugs in a clique. If Dti < DC we suggest that test drug and ith
clique drug are possibly synergistic and include them into “suggested synergies”
set. After suggested synergies are dtermined, a classification algorithm is used
to make the final decision. Next, we will present the details of the classification
algorithm used for this purpose.
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3.3.2 Classification
Data: suggested synergies
Result: predicted synergies
for all drugs in dataset do
select subset W of suggested synergies ;
calculate scores for members of W ;
select high score members as final predictions
end
Algorithm 2: Topological based synergy prediction - predicting synergistic pairs
A subset, W, of most frequent suggestions for each test drug was extracted from
suggested synergies set. Subset W has a size, p, which is an indicator of connec-
tivity of a drug in the network,
p = bavg(synergicity) ∗ (ND − 1)c
largest integer before(floor) average synergycity score in the network multiplied
by ND − 1 which is number of drugs excluding test drug. . For example if drug
#7 is selected as the test drug, average synergicity equals to 0.35 and p = 6.
Three scores were extracted from distance matrices to identify candidate syner-
gistic drug(s) from W.
• Synergicity is number of synergies a candidate drug shows in all experiments
that has been done on it.
• Difference score for synergistic network
• Difference score for antagonistic network
When two drugs are included in suggested synergies set,
DC −Dt
mean(distance matrix)
is added to a separate vector which we call as “difference vector”. Average “differ-
ence vector” values of items in W were calculated to form Difference score for each
member of W set. This vector was also created using distance matrices obtained
from antagonistic network. A higher difference score in synergy network and a
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lower score in antagony network, indicates that test drug is more affine to have
synergy with the drug in W, thus, when combining these two scores, antagonistic
scores will have a negative coefficient.
Synergy Index is a normalized weighted sum of three scores. Average synergy
index of all drugs in W added to a percentage of their standard deviation was
used as a threshold to determine final synergies. Percentage of used standard
deviation is different in yeast and E. Coli datasets. In E. Coli dataset 100% and
in yeast dataset 75% of of standard deviation was added to the average synergy
index. Percentages of standard deviation was determined empirically.
3.4 Results for E. Coli
Employing this method on E. Coli dataset resulted in 566 members of suggested
synergy set for synergy network and 759 for antagonistic network. Suggested
synergies has 215 unique members for synergy network and 260 for the antagony
network. Size of W set varies between 8-9 suggestions for this dataset. Synergy in-
dex was calculated using weights equal to 0.5 for synergicity and synergy difference
scores and -0.5 for antagony difference score. Table 3.6 represents confusion matrix
after applying the method on original network. A confusion matrix is a table that
represents performance of an algorithm. Each column of the matrix indicates the
instances in a predicted class while each row represents actual instances. Table
3.5 represents the elements of a confusion matrix.
• true positives (TP): These are the cases in which the classifier correctly
predicts interaction to be synergistic, and it is synergistic in reality.
• true negatives (TN): These are the cases in which the classifier correctly
predicts interaction to be non-synergistic, and it is non-synergistic in reality.
• false positives (FP): The classifier predicts synergy but the interaction is
non-synergistic in reality.
• false negatives (FN): The classifier predicts non-synergy but the interaction
is synergistic in reality.
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Table 3.5: Structure of a confusion matrix.
Predicted(P) Predicted(N)
Actual(P) TP FN
Actual(N) FP TN
Table 3.6: Confusion matrix after network based classification on E. Coli
dataset.
147 4
11 9
Base accuracy rate is defined as
Base accuracy rate =
Size of major class
Total number of instances
Major class is the output class of the classifier which has the highest instances in
data set. Base accuracy rate indicates accuracy value in case that the classifier
outputs the major class for every input In this dataset 20/171 interactions belong
to the positive, i.e., synergistic class which makes base accuracy rate equal to
20/171 Area Under ROC curve for this result and accuracy are 0.71 and 0.91,
respectively, in which accuracy is more than base rate of 0.88.
As an alternative approach, the method used in [2] was implemented in order to
verify the results. We conducted the analysis on node-shuﬄed and edge-shuﬄed
networks for 1000 iterations. Edge shuﬄed network has the same number of nodes
as the original network but the links between nodes are randomly distributed.
Node-shuﬄed network on the other hand has the same topology of edges but node
labels are shuﬄed. Since more information is lost in edge shuﬄed network we
expect when we shuﬄe edges, performance of the classifier be lower than the node-
shuﬄed network. At the same time original network’s classification performance
should be better than node-shuﬄed’s as node label information is lost in this
network. Figure 3.6 represents the results of 1000 randomizations for both node
and edge-shuﬄed networks. AU-ROC of node shuﬄed was more than the original
network in 42/1000 of the trials. As there is no randomization for the original
network we performed the analysis once.
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Figure 3.5: Area Under ROC curve for of 1000 iterations of the method on
edge-shuﬄed (blue), node-shuﬄed (green) and original network(black). The real
counts value for original graph is one.
Figure 3.6: Area Under ROC curve for of 1000 iterations of the method on
edge-shuﬄed (blue), node-shuﬄed (green) and original network(black). The real
counts value for original graph is one.
3.5 Results for yeast
Employing this method on yeast dataset resulted in 556 members of suggested
synergy set for synergy network and 773 for antagonistic network. Suggested
synergies has 179 unique members for synergy network and 260 for the antagony
network. Size of W set varies between 8-9 suggestions for this dataset, except for
the time that drug # 2 is selected as test drug. Synergy index was calculated
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Figure 3.7: Predicted synergy network for E. Coli. Nine synergies were pre-
dicted correctly (green), 11 synergies could not be predicted (red), and four
non-synergies were predicted as synergy (black)
Table 3.7: Confusion matrix after network based classification on yeast
dataset.
43 7
9 8
using weights equal to 0.5 for synergicity and synergy difference scores and -0.5
for antagony difference score. Table 3.7 represents confusion matrix after applying
the method on original network.
In this dataset 17/67 interactions belong to the positive, i.e., synergistic class
which makes base accuracy rate equal to 50
67
= 0.75 Area Under ROC curve for
this result and accuracy are 0.66 and 0.76, respectively, in which accuracy is more
than base rate of 0.75.
Table 3.7 represents confusion matrix after applying this methon on yeast dataset.
Figure 3.8 represents the results of 1000 randomizations for both node and edge-
shuﬄed networks. AU-ROC of node shuﬄed was more than the original network
in 581/1000 of the trials. As there is no randomization for the original network
we performed the analysis once.
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Figure 3.8: Area Under ROC curve for of 1000 iterations of the method on
edge-shuﬄed (blue), node-shuﬄed (green) and original network(black). The real
counts value for original graph is one.
Chapter 4
Non-topological Methods
4.1 Introduction
In this chapter of the thesis we have used two meta-heauristic algorithms for
feature reduction and prediction of synergistic pairs. A brief review of the used
algorithms will be provided in Section 4.2, results of employing such methods are
represented in Section 4.3. Genetic Algorithm was only used to find a subset
of available features which provide a better objective function. Details of the
objective function will be provided in Section 4.2. GRASP algorithm was uswd
only on E. Coli dataset. In order to predict interaction types using the feature
subset found by GRASP, decision tree and KNN classifiers were used.
4.2 Algorithms
4.2.1 Genetic Algorithm
Genetic algorithms are a subset of a larger class of meta-heuristic algorithms called
evolutionary algorithms. In these algprithm natural selection is inspired from bi-
ological evolution. Biological functions such as reproduction, mutation and selec-
tion is common in this type of methods. GA is especially beneficial in solving the
problems in which the solution space is significantly large and fitness landscape
is complex, i.e., there are many local optimal solutions. Mutation process in GA
allows the algorithm to avoid remaining in the local optima and look for more or
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global optimal solutions. A solution is usually called an individual and a subset
of the solution space that algorithm preforms on is called a population or a pool
of solutions. Fitness function is designed in such a way that represents the value
of objective function of an individual. A crossover operator produces next pop-
ulation by incorporating more than one parent solutions. Children solution are
referred to as offsprings in GA terminology. There are different types of perform-
ing a crossover on an individual. In this thesis we have used two-point crossover
procedure in which children solution is created by two parts of first parent and
one part from the second one, as depicted in Figure 4.1.
Figure 4.1: Two point crossover used in this analysis.
Locations of crossover are determined randomly in each iteration of GA. A muta-
tion operator simulates the biological mutation phenomenon by randomly changing
some parts of the offspring individuals, Figure 4.2 depicts a simple example of mu-
tation in two points of a solution.
Figure 4.2: Mutation randomly changes some part of the solution.
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We define selected subset of a chemogenomic profile which is defined by a solution
as “sub-profile”. In this study, our objective function is defined as correlation
between sub-profiles and alpha scores of the drug interactions in both E. Coli and
yeast chemogenomic datasets.
A genetic algorithm with two-point crossover, one percent mutation was used in
10000 iterations. Probability of doing a crossover and a mutation was 0.5 in each
iteration and when a mutation was going to happen 1% of solution pool was
mutated. Algorithm 3 represents steps taken in this algorithm.
Data: chemogenomic profiles
Result: sub-profile
create initial pool;
for number of iterations do
calculate fitness function for all pool solutions;
find best and worst fitness solutions;
crossover on best solutions − > new solutions;
exchange worst reslts with new solutions ;
mutate the pool ;
end
Algorithm 3: Genetic algorithm for sub-profile selection
4.2.2 GRASP
GRASP is a commonly used meta-heuristic algorithm in optimization problems.
GRASP algorithm consists of two phases. First is to create a feasible solution,
and the second phase in which local optimum is searched in neighborhood of the
feasible solution found in the first phase. Each iteration of the algorithm provides a
solution to the problem at hand. Since GRASP selects the best possible solutions,
is categorized as a greedy algorithm. In every iteration of the algorithm a random
solution of non-best solutions is added into a selected set of solutions with highest
value of objective function. This set is then used for further steps of searching the
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feasible region. A generic GRASP procedure is represented in Algorithm 4.
create initial solution;
for GRASP stopping criterion is not satisfied do
construct greedy randomized solution ;
local search;
update solution ;
end
return best found solutions
Algorithm 4: Generic GRASP algorithm procedure [22].
In order to select a subset of features that can help us predict synergistic inter-
actions, we have implemented GRASP on E. Coli and yeast datasets. In the first
phase of the method, we select a subset of length two from available features,
feature i and j. For each drug interaction, k, we select ith and j th element in
the chemogenomic profiles of the drugs involved in the interaction to calculate
the correlation between these two sub-profiles. We defined correlation vectors as
pairwise correlation between sub-profiles of the drugs in an interaction. Figure 4.3
represents depicts the process to calculate correlation vectors. In Figure 4.3 drugs
x and y are two drugs in interaction k.
Figure 4.3: Element k in the correlation vector is a result of correlation be-
tween elements i and j in feature vectors x and y
After calculating all elements of the correlation vector, q, we calculate the correla-
tion between alpha scores and q which is the value of fitness function for GRASP.
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Fitness values vector and q have the same length equal to number of the interac-
tions.
Fitness value indicates similarity between alpha scores and feature vector using
only ith and j th feature instead of all. Similarly we can calculate fitness values
for a subset of more than two features.
In the first part of the method, We find the fitness value for all possible couples of
features, with length of
(
3979
2
)
= 7914231. As we expect features which represent
alpha scores better will be more successful in the classification process, we select
a subset of n feature couples with highest fitness values.
A random couple out of n is selected in the beginning of the second part to start an
experiment. In each iteration of the experiment one feature is added to the subset
of selected features. Starting from the first feature we check whether it has been
already selected or not. If it has not been used before, we concatenate that feature
to the subset of selected features and objective values are calculated using new set
of selected features. We select k features which yielded best objective values and
due to the nature of GRASP algorithm we add one feature which has not been
among k best objective values. Adding features is continued until a predefined
limit, F, is reached in an experiment. E experiments will be done and the best
result is reported. Figure 4.4 represents the steps of each experiment.
4.2.3 KNN classifier
K-Nearest Neighbors algorithm is an instance-based classification method, i.e.,
it stores all available cases and classifies new cases based on a similarity mea-
sure ,e.g., distance functions [23] Classification using an instance-based classifier
is performed by locating the nearest neighbor in instance space and labeling the
unknown instance with the same class label as that of the located neighbor in
training data. A disadvantage in using this approach its sensitivity to the noise in
training data.
In order to achieve more robust models, location of k, where k ¿ 1, neighbours can
be considered and majority vote can decide the outcome of the class labelling. A
higher value of k results in a smoother, less locally sensitive, function. The nearest
neighbour classifier can be regarded as a special case of the more general k-nearest
neighbours classifier, hereafter referred to as a kNN classifier.
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Figure 4.4: Flowchart of experiments done using GRASP algorithm in second
part of feature selection method
4.3 Results
4.3.1 GA Results
In case of E. Coli, objective value was -0.24 before performing GA and the rela-
tionship between correlation of chemo-genomic profiles and alpha scores was as
depicted in Figure 4.5
Fitness function value was decreased to -0.58 by applying GA. Fitness function for
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Figure 4.5: Correlation of chemo-genomic profiles versus alpha scores of drug
interactions before applying genetic algorithm in E. Coli dataset
each iteration is depicted in Figure 4.6. Relationship between correlation vector
and alpha scores after GA in E. Coli dataset is represented in 4.7.
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Figure 4.6: Fitness function in each iteration of GA in E. Coli dataset
Size of selected sub-profile is around 1600 features. By applying genetic algorithms
we could select a subset of features by which the value of objective function has
been minimized.
For yeast before applying genetic algorithm, using 67 out of 231 possible drug
interactions, value of objective function was -0.15. A genetic algorithm with two
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Figure 4.7: Relationship between alpha scores and sub-profiles after GA in E.
Coli dataset
point crossover function and 1% mutation was performed for 20000 and the max-
imum absolute value of objective function in each iteration were as depicted in
Figure 4.8
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Figure 4.8: Value of objective function in each iteration of genetic algorithm
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Table 4.1: Parameters used for GRASP algorithm
Number of experiments 20
Number of selected features 32
Number of best features selected 5
n 100
Table 4.2: Parameters used for GRASP algorithm
Number of experiments 10
Number of selected features 20
Number of best features selected 5
n 100
4.3.2 GRASP results
Figure 4.9 represent the final output of feature reduction procedure using the
parameters stated in Table 4.1 for the model.
Figure 4.9: Objective value has decreased by using the features selected by
GRASP with parameters stated in Table ??.
We tried another set of parameters but fitness value was not improved, Table
4.2 represents used parameters and Figure 4.10 depicts the relationship between
correlation vector and alpha scores.
In order to verify that using selected features yields in a better classification accu-
racy, we predicted interaction types using desicion tree and KNN classifiers. These
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Figure 4.10: Objective value has decreased by using the features selected by
GRASP with parameters stated in Table 4.2
Table 4.3: Confusion matrix after using
148 3
7 13
two common classifiers voted for the type of each of 165 interactions, i.e. if both of
them predicted the interaction to be synergistic, the final output is synergy. PR
Tools [24] was used as a means to perform the classification, 5-fold cross validation
and voting procedure.
Selected features of experiments were sorted and the subset which leads to the
best objective function was selected, i.e., the same feature set related to Figure 4.9.
Since value of objective function is not strictly increasing inside the selected subset,
a reduced subset of features were selected. Reduced subset contains members of
the original subset from the first member to the one that leads to the best fitness
function. Since in our analysis the best fitness function was the last member of
the feature subset, reduced subset contained all 32 selected features.
Correlation vector was calculated using selected features and was introduced to the
voting classifiers. Binarized alpha-scores with threshold -0.5, which is extraced fron
expert knowledge, was used as the labels for learning. 4.3 represents the confusion
marix of our analysis. Area Under ROC equal to 0.82 and Area Under PR curve
of 0.87.
Chapter 5
Utilizing Chemical Features
5.1 Introduction
Chemical features of drugs participating in an interaction can be used as a means
to predict synergy. These features are based on chemical formulations and can be
calculated mathematically which makes them significantly more reliable in com-
parison to the features based on experiments. It has been seen that if a feature
is correlated significantly with synergicity, it can be a leading to more accurate
predictions. Drug lipophilicity is an example of such features and has been used
in [2]. Lipophilic drugs have a higher tendency to be synergistic with other drugs
[2]. In this chapter we reproduced results found in [2] with a different classifier
in first step and selected a new feature, Q PC-, from a subset which consisted of
327 drug descriptors. We found that although Q PC- is not neither correlated
with lipophilicity nor synergicity, using it will yield in good classification results.
Decision tree and random forests were used in order to perform the classification.
Details of the methods used will be discussed in the following sections.
5.2 Classifiers
In this section a brief introduction to the used classification methods will be pro-
vided.
40
Utilizing Chemical Features 41
5.2.1 Decision tree
Decision tree classifiers use graphs in tree format to model possible outcomes of a
datum based on attributes it possesses . Each internal node in the tree represents a
test on the data attribute and based on the criterion which is calculated using the
value of that attribute, a branch is made. When all data attributes are considered
or a stop condition is met, a label(an outcome) is assigned to the datum. Final
nodes of a decision tree, i.e. assigned class labels, are called leaves of the tree.
If nodes of the tree are traced from root to the leaves, a decision rule can be
generated. Decision rules verbally express the rules generated by the decision
tree algorithm. Figure 5.1 depicts an example of a trained decision tree on “play
tennis” dataset. This dataset consists of weather conditions and labels which
state whether it is suitable to play tennis or not. Leaves of this tree represent the
decision that is suggested by the algorithm. Based on this decision tree We can
generate a decision rule which states “if outlook is sunny and humidity is normal,
it is suitable to play tennis today”. If a node is closer to the root of a tree, it
contains more valuable information than the one that is further.
Figure 5.1: An example of a trained decision tree for “play tennis” dataset
In the analysis that we have done in this chapter, nodes of the trained decision
tree consists of the chemical features of first and second drug in a test interaction
and the output is based on the chemical attributes are they synergistic or not.
MATLAB’s default implementation of decision trees has been used to train the
models.
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5.2.2 Random Forest
A random forest uses an an ensemble of decision trees in training phase. Median of
outputs from these individual trees are reported as the final label random forest has
generated. Each tree in the ensemble is trained by using a subset of input variables,
i.e., if there are V variables in input data, a subset v of these variables is selected
randomly with replacement to branch the nodes of the trees in an ensemble [25].
Using random forests can avoid over-fitting that is a common problem in decision
tree algorithm. They also perform better in unbalanced datasets [25]. In an
unbalanced dataset, majority of training set consists of data from one class, thus,
the classifier has a tendency to label test data as the majority class. Performance
on unbalanced datasets is an important factor in selecting classification methods.
In our analysis we have used the random forest implemented in WEKA toolkit
[26].
5.3 Chemical features
5.3.1 Lipophilicity feature
Lipophilicity, XLogP3, of drugs has a significantly high correlation with drug
synergicities, Figure 5.2. The method used in [2] to predict synergy in yeast dataset
was replicated with random forest classifier of WEKA toolkit [26] in MATLAB.
The feature vector introduced to the random forest classifier was XLogP3 value
of first drug concatenated with XLogP3 value of the second drug and vice versa,
i.e. we added values of second drug concatenated with first to the bottom of the
previous vector. As there were 165 interactions available in yeast dataset, total
number of rows of (observations) in the feature vector was 2 ∗ 165 = 330, Figure
5.3. WEKAs random forest was used in MATLAB with the following settings
• Unlimited depth of trees
• 2 features to be used in random selection
• 100 as the number of trees to be trained
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Figure 5.2: XLogP3 has a significantly high correlation with synergicity,
Spearman r = 0.51 , p = 0.0036
Figure 5.3: Feature vector introduced to random forest classifier.
5.3.2 Q PC- Feature
We observed features which are not correlated with synergicity can be equally a
good means to predict interaction types. Q PC- is one of these features that is
neither correlated with synergicity nor lipophilicity, Figure 5.4.
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Figure 5.4: Q PC- is not correlated with XLogP3 nor synergicity.
Figure 5.5: Q PC- features were used in the classifier by concatenating the
both values for Q PC- of drugs involved in an interaction
We used the same pattern of concatenating the features of first and second drugs
to be introduced to classifier, Figure 5.5. If we apply a simple rule based on Figure
5.5 to identify interactions with Q PC- value of more than -6 for both drugs as
synergistic, an AU-ROC of 0.55 will be achieved. This result promises that if
the random forest divides the feature space into more accurate subspaces, more
accurate predictions can be obtained.
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5.4 Results
5.4.1 E. Coli Results
Resulted AU-ROC and AU-PR curve of performing 10-fold cross validation for
300 iterations are represented in Figures 5.6 and 5.7 respectively.
Figure 5.6: Distribution of AU-ROC when using random forest as a classifier
along with XLogP3 as feature.
Figure 5.7: Distribution of AU-PR when using random forest as a classifier
along with XLogP3 as feature.
In Figures 5.6 and Figure 5.7 black color represents the results for the original,
green for the node shuﬄed and blue for the edge shuﬄed synergy graph. As
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Figure 5.8: AU-ROC when using Q PC- feature in a random forest classifier.
Maximum AU-ROC for original network is 0.86
described in Chapter 3, the results are as expected, i.e. original graph’s AU-ROC
is more than node-shuﬄed AU-ROC and node-shuﬄed AU-ROC is more than
edge-shuﬄed AU-ROC. By adopting random forest as the classification method,
maximum AU-ROC for original network was improved from 0.80 in [2] to 0.87 and
maximum AU-PR to 0.79.
5.4.2 Q PC- Results
A similar random forest was applied to the feature space and the results in Figures
5.8 and 5.9 were achieved for AU-ROC and AU-PR respectively. Analyses were
repeated for 300 iterations of 10 fold cross validation. Reviewing the AUROC
distribution suggests that Q PC- can be a as discriminative in predicting synergies
as XLogP3. In order to further investigate this feature we conducted the analyses
using decision trees in MATLAB with default settings and obtained similar results.
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Figure 5.9: AU-PR when using Q PC- feature in a random forest classifier.
Chapter 6
Discussion and Conclusion
In this thesis, we studied the drug synergy prediction problem in two important
datasets, E. Coli and yeast. Chemogenomic profiles and chemical drug features
were used in the analysis. We used three different approaches.
In our first survey, we introduced a new method in Chapter 3 to predict synergies
based on the topological information gained from chemogenomic profiles in both
E. Coli and yeast datasets. This algorithm resulted in Area Under ROC curve and
the accuracy of 0.71 and 0.91, respectively, in E. Coli dataset.
Next, in Chapter 4 we used meta-heuristic algorithms for feature subset selection
and synergy prediction in E. Coli dataset. We employed genetic algorithm with
two point crossover procedure to select a subset of features and maximize the
defined objective function. In the second part of the chapter, we defined a GRASP
algorithm to the first perform feature subset selection and predict synergies in E.
Coli dataset in the second step. Applying this method yielded in 0.94 accuracy
and 0.82 Area Under ROC curve for E. Coli dataset.
Finally, Chapter 5 was dedicated to utilize chemical features. We used decision
trees and random forest in order to predict synergies in yeast dataset. Two chem-
ical features were utilized, XLogP3 and Q PC-. Our analysis suggests that Q PC-
chemical feature can be as discriminative as XLogP3, despite the fact that Q PC-
does not have a significant correlation with synergicity scores of the drugs. XLogP3
has been used in literature previously [2]. It has been seen that utilizing XLogP3
will lead to more accurate predictions in yeast dataset.
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We observed that utilizing chemical features in yeast dataset results in more ac-
curate synergy predictions in comparison to other methods. A future step can
perform the same analysis on E. Coli dataset. More chemical features can also
be explored to find other discriminateive features. In topological based methods
introduced in Chapter 3, more scores can be extracted from distance matrices to
observe their effect on the final accuracy of predictions.
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